Kyverna Therapeutics, Inc. (KYTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
KYTX currently has 60.4M outstanding shares. with significant dilution risk as 87M authorized shares could dilute existing holders by 143.9%. The company has significantly diluted shareholders by 39.85% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 60.4M shares outstanding |
60M | 87M |
| Mar 26, 2026 |
10-K filing | 60.4M shares outstanding |
60M | 36M |
| Mar 26, 2026 |
S-3 filing: Kyverna Therapeutics, Inc. files an S-3 registration statement for the potential offering of common stock, preferred stock, debt securities, warrants, rights, units, and depositary shares, with an aggregate initial offering price not to exceed $300,000,000. |
60M | 87M |
| Nov 12, 2025 |
10-Q filing | 43.4M shares outstanding |
43M | 36M |
| Aug 12, 2025 |
10-Q filing | 43.2M shares outstanding |
43M | 36M |
| May 13, 2025 |
10-Q filing | 43.2M shares outstanding |
43M | 36M |
| Mar 27, 2025 |
10-K filing | 43.2M shares outstanding |
43M | 36M |
| Mar 27, 2025 |
S-3 filing: Kyverna Therapeutics, Inc. files an S-3 to offer common stock, preferred stock, debt securities, warrants, rights, units, and depositary shares, with a total offering price not exceeding $250,000,000; also offering up to $50,000,000 of shares of common stock through an at the market offering. |
43M | 36M |
| Nov 13, 2024 |
10-Q filing | 43.2M shares outstanding |
43M | 15M |
| Aug 12, 2024 |
10-Q filing | 43.1M shares outstanding |
43M | 15M |
| May 14, 2024 |
10-Q filing | 43.1M shares outstanding |
43M | 15M |
| Feb 06, 2024 |
S-1/A filing: S-1/A filing for an offering of common stock. |
26M | 15M |
| Feb 01, 2024 |
S-1/A filing: This S-1/A filing includes information about a potential offering of common stock, with 11,120,000 shares being sold by the company. It also mentions the shares outstanding and discusses potential sales of shares by existing stockholders. |
37M | 11M |
| Jan 16, 2024 |
S-1 filing: This is an S-1 filing for an offering of common stock underwritten by J.P. Morgan, Morgan Stanley, Leerink Partners and Wells Fargo Securities. The filing mentions the conversion of preferred stock to common stock and includes a lock-up agreement for existing stockholders. |
120M | 0 |